|1.||Mencarelli, Andrea: 1 article (05/2005)|
|2.||Morelli, Antonio: 1 article (05/2005)|
|3.||Wallace, John: 1 article (05/2005)|
|4.||Fiorucci, Stefano: 1 article (05/2005)|
|5.||Farneti, Silvana: 1 article (05/2005)|
|6.||Santucci, Luca: 1 article (05/2005)|
09/01/1999 - "NO-mesalamine was significantly more effective than mesalamine in reducing the severity of colitis (damage and granulocyte infiltration). "
05/01/2005 - "NCX-456, but not mesalamine, administration resulted in a marked reduction in clinical, histological, and immunologic signs of colitis in both models. "
09/01/1999 - "Effects of an NO-releasing derivative of mesalamine (NCX-456; NO-mesalamine) were compared with those of mesalamine itself and 2 other NO donors in a rat model of colitis. "
05/01/2005 - "Cells and tissues from mice with 2,4,6-trinitrobenzene sulfonic acid-induced colitis and from interleukin 10-deficient mice with spontaneous chronic colitis receiving treatment with several doses of NCX-456 or mesalamine were analyzed for morphology, cytokine production, and apoptosis. "
|2.||Interleukin-10 (Interleukin 10)
|3.||Transforming Growth Factor beta (TGF-beta)